A study in the Archives of Neurology found the experimental drug bapineuzumab reduces levels of phosphorylated tau in spinal fluid, suggesting it might do the same in the brain and affect tangles associated with Alzheimer's disease. Alzheimer's disease experts who commented on the University of Gothenburg preliminary study said it was too soon to draw any conclusions about whether the drug could stop or even slow the degenerative process of Alzheimer's disease.

Full Story:

Related Summaries